share_log

6-K: H1 and Q2 2024 Results

6-K: H1 and Q2 2024 Results

6-K：2024上半年和第二季度业绩
美股SEC公告 ·  2024/07/25 21:09

Moomoo AI 已提取核心信息

AstraZeneca reported robust H1 2024 performance with Total Revenue increasing 18% (CER) to $25.6B, driven by 18% growth in Product Sales and continued Alliance Revenue expansion. Core EPS grew 5% to $4.03, while Product Sales Gross Margin maintained at 82%.Growth was broad-based across therapeutic areas, with Oncology up 22%, CVRM up 22%, R&I up 22%, and Rare Disease up 15%. Key growth drivers included Farxiga (+38%), Ultomiris (+35%), and Enhertu (+62%). The company announced five positive Phase III studies that are expected to contribute meaningfully to future growth.Based on strong underlying performance, AstraZeneca upgraded its FY 2024 guidance, now expecting both Total Revenue and Core EPS to increase by mid-teens percentage at CER. The company declared an interim dividend of $1.00 per share, up 7 cents. Strategic investments included plans for a $1.5B ADC manufacturing facility in Singapore and acquisitions of Fusion Pharmaceuticals and Amolyt Pharma to strengthen the pipeline.
AstraZeneca reported robust H1 2024 performance with Total Revenue increasing 18% (CER) to $25.6B, driven by 18% growth in Product Sales and continued Alliance Revenue expansion. Core EPS grew 5% to $4.03, while Product Sales Gross Margin maintained at 82%.Growth was broad-based across therapeutic areas, with Oncology up 22%, CVRM up 22%, R&I up 22%, and Rare Disease up 15%. Key growth drivers included Farxiga (+38%), Ultomiris (+35%), and Enhertu (+62%). The company announced five positive Phase III studies that are expected to contribute meaningfully to future growth.Based on strong underlying performance, AstraZeneca upgraded its FY 2024 guidance, now expecting both Total Revenue and Core EPS to increase by mid-teens percentage at CER. The company declared an interim dividend of $1.00 per share, up 7 cents. Strategic investments included plans for a $1.5B ADC manufacturing facility in Singapore and acquisitions of Fusion Pharmaceuticals and Amolyt Pharma to strengthen the pipeline.
阿斯利康公布了2024年上半年的强劲表现，总营业收入按可比汇率增长18%，达到256亿美元，这主要得益于产品销售增长18%和联盟收入的持续扩展。每股核心收益增长5%，达到4.03美元，而产品销售毛利率维持在82%。各治疗领域的增长面广泛，肿瘤科增长22%，心血管肾脏病增长22%，呼吸及免疫增长22%，罕见病增长15%。主要增长动力包括Farxiga (+38%)，Ultomiris (+35%)和Enhertu (+62%)。该公司宣布了五项积极的第三阶段研究，预计将对未来的增长产生重要贡献。基于强劲的基础表现，阿斯利康上调了2024财年的预测，现在预计总营业收入和每股核心收益均将按可比汇率增长中等十位数的百分比。该公司宣布每股中期股息为1.00美元，增加7美分。战略投资包括在新加坡建设15亿美元的ADC制造设施和收购Fusion Pharmaceuticals和Amolyt Pharma以强化管道。
阿斯利康公布了2024年上半年的强劲表现，总营业收入按可比汇率增长18%，达到256亿美元，这主要得益于产品销售增长18%和联盟收入的持续扩展。每股核心收益增长5%，达到4.03美元，而产品销售毛利率维持在82%。各治疗领域的增长面广泛，肿瘤科增长22%，心血管肾脏病增长22%，呼吸及免疫增长22%，罕见病增长15%。主要增长动力包括Farxiga (+38%)，Ultomiris (+35%)和Enhertu (+62%)。该公司宣布了五项积极的第三阶段研究，预计将对未来的增长产生重要贡献。基于强劲的基础表现，阿斯利康上调了2024财年的预测，现在预计总营业收入和每股核心收益均将按可比汇率增长中等十位数的百分比。该公司宣布每股中期股息为1.00美元，增加7美分。战略投资包括在新加坡建设15亿美元的ADC制造设施和收购Fusion Pharmaceuticals和Amolyt Pharma以强化管道。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    施贵宝
    BMY
    -- 60.020
    默沙东
    MRK
    -- 89.230
    赛诺菲安万特
    SNY
    -- 55.820
    阿斯利康
    AZN
    -- 73.790
    艾伯维公司
    ABBV
    -- 205.290
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日